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S262 Poster Session ITable 1. Correlation coefficients for parameters measured on
fresh cord blood (all p<0.0001).
TNC CFU MNC ALDHbr CD34TNC 1.00 0.70 0.82 0.58 0.50
CFU 0.70 1.00 0.61 0.66 0.60
MNC 0.82 0.61 1.00 0.47 0.41ALDHbr 0.58 0.66 0.47 1.00 0.70
CD34+ 0.50 0.60 0.41 0.70 1.00Conclusions: In this large cohort, measured fresh CB parameters
correlated well and predicted each other. Furthermore, ALDHbr
correlated well with CFUs and is a promising surrogate for CFUs
as a potency assay given the technical difficulties with the CFU assay.
In fresh CB, ALDHbr content was modestly more reliable in pre-
dicting CFUs than CD34+. We and others have shown before that
cells survive freezing and thawing with different efficiencies. We
continue to study which parameters, individually or combined, cor-
relate best with engraftment when measured on attached CBU seg-
ment or after unit thaw in order to improve potency assessment
during the final stages of donor selection.
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CYCLOPHOSPHAMIDE PRIMING WITH INTRAVENOUS PLERIXAFOR AND
GCSF MOBILIZATION FOR MULTIPLE MYELOMA
Krishnan, A.1, Wang, S.1, Htut, M.1, Farol, L.2, Palmer, J.3, Quazi, I.3,
Forman, S.1, Tsai, N.1, Forman, S.1 1City of Hope Cancer Center,
Duarte, CA; 2Southern CA Kaiser/City of Hope, Duarte, CA; 3City of
Hope, Duarte, CA
Background: Plerixafor (Pl), an inhibitor of CXCR4 has been ap-
proved for use with G-CSF for stem cell mobilization for autologous
transplant in patients withmultiplemyeloma and non-Hodgkin lym-
phoma. However, the subcutaneous route of injection necessitates
dosing 11 hours prior to apheresis. Intravenous (IV) dosing may re-
sult in a faster peak CD34+ cell count allowingmore convenient dos-
ing. Other strategies to increase stem cell yield include
chemotherapy mobilization with cyclophosphamide (CY). Herein
we report on the use of CY followed by intravenous Pl plus G-CSF.
Methods: The primary objectives were safety and efficacy of intra-
venous administration of Pl following CY mobilization in pts with
myeloma. The secondary endpoint was the ability to collect .5 x
106 CD34+ cells/kg in two or fewer days. Patients received CY
1.5g/m2 followed byG-CSF (10mg/kg) 24 hrs post chemo. Apheresis
commenced 10 days post CY, Pl IV (0.16-0.24mg/kg) was given on
the morning of apheresis, 4-6 hrs prior to apheresis. Peripheral
CD34+ cell counts were drawn just before Pl administration and at
1- 4 hr time points post.
Results: Eleven patients have been enrolled to date and are available
for analysis;median age is 59.2 (range: 43.4 – 68.9) years, median no. of
prior therapies is 1 (range: 1-3). Three pts were treated with 0.16mg/
kg, 8 with 0.24mg/kg of Pl. Eight patients had prior lenalidomide and
9 had prior bortezomib. Disease status at entry was 2 CR, 1MR, 6 PR
and 2 VGPR. CD34 counts increased a median of 1.8 fold (range: 1.1-
2.9) 1 hr post the first IV dose.
Seven of eleven pts met the secondary endpoint. Nine pts have been
transplanted and all engrafted at a median of 11 days (range 10-12) for
neutrophil engraftment and 16 days for plts (range 8-22). Grade 3/4
non heme toxicities occurred in ten pts and included emesis, anorexia,
hyperglycemia, hyperuricemia, hyponatremia and bone pain.
Conclusions: The adverse event profile and efficacy of IV Pl post
chemotherapy is similar to subcutaneous administration, with the ex-
ception of chemo related toxicities and allows for same day dosing of
Pl as apheresis.158
HIGH-RESOLUTION MULTIDIMENSIONAL PROTEOMIC ANALYSIS OF
CIRCULATING BIOMARKERS IN PATIENTS WITH ACUTE GRAFT-VER-
SUS-HOST DISEASE (aGVHD)
Lemos, G.1,5, Pizzatti, L.1,3,4,5, Pinto, D.O.1,4, Bouzas, L.F.2,5,
Abdelhay, E.1,3,5 1Bone Marrow Transplantation Unit (CEMO) -INCA, Rio de Janeiro, Brazil; 2Bone Marrow Transplantation Unit
(CEMO) - INCA, Rio de Janeiro, Brazil; 3Proteomics Network of Rio
de Janeiro, Rio de Janeiro, Brazil; 4Sociedade Beneficente Israelita Brasi-
leira Hospital Albert Einstein, Sao Paulo, Brazil; 5National Cancer Insti-
tute (INCA), Rio de Janeiro, Brazil
Introduction:The graft-versus-host disease is a serious complication
of allogeneic hematopoietic stem cells transplantation (HSCTs) and
the major cause of morbidity and mortality in patients undergoing
this therapy. The diagnosis of aGVHD is still carried out by clinical
observations followed by biopsies of injured organs. Thus, studies
that aim to identify potential biomarkers for aGVHD are needed.
Multidimensional proteomic strategies on a large scale have been
widely used for the identification and quantification of biomarkers in
different diseases. Therefore the identification and absolute quantifi-
cation of proteins and peptides differentially expressed in the plasma
of patients who developed aGVHD, is extremely important.
Objective: Compare and quantify the protein expression profile of
the patients plasma after allogeneic HSCT comparing patients
who developed aGVHD with those that did not develop aGVHD
and the plasma of healthy donors.
Materials and Methods: This study analyzed 73 plasma samples of
patients who underwent allogeneic HSCT at D+45 and 50 plasma
samples from healthy donors. 31 samples had acute myeloid leuke-
mia (AML) as underlying disease, 21 patients developed aGVHD
and 10 patients did not develop aGVHD. 42 patients had as under-
lying disease acute lymphoblastic leukemia (ALL), 24 and 18 devel-
oped aGVHDor did not develop aGVHD respectively. The samples
were concentrated 16x with 3k Amicon columns (Millipore) and
digested in solution and analyzed bymultidimensional chromatogra-
phy (MudPIT) in mass spectrometry-2D-NanoESI MSE (MudPIT)
using Synapt HDMS mass spectrometer (Waters). The proteins
were identified and quantified using the software Proteinlynks
Global Server (Waters) with the tool Expression E.
Results and Conclusions: We identified 99 and 109 proteins in
AML and ALL respectively. Differential expression analysis identified
102 proteins between the pools of samples compared. Among the pro-
teins identified protein NALP2 stands out as a possible biomarker of
aGVHD in patients who had AML as the underlying disease.
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IMPACT OF GRAFT CD34 CELL DOSE ON CHRONIC GRAFT-VERSUS-HOST
DISEASE (cGVHD) AND PREDICTIVE VALUES OF CD3 CELL DOSE AND
DAY 56 CHIMERISM ON SURVIVAL IN NONMYELOABLATIVE (NMA) AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
Pecheux, L., Ahmad, I., Baron, C., Busque, L., Cohen, S., Kiss, T.,
Roy, D.-C., Roy, J., Sauvageau, G., Lachance, S. Ho^pitalMaisonneuve-R-
osemont, Montreal, QC, Canada
Purpose:Compared tomyeloablative regimensNMAHSCT is asso-
ciated with decreased toxicity but higher incidence of cGVHD and re-
lapse. The optimalCD34+ cell dose inNMAHSCTand the impact of
graft composition on transplant outcome remains controversial.
We studied the influence of graft composition, engraftment kinet-
ics and post-transplant chimerism on outcomes in this setting.
Methods: We retrospectively analyzed graft composition and chi-
merism data in a homogenous cohort of 81 consecutive patients
treated for multiple myeloma with HLA-matched sibling NMA
HSCTafter a conditioning regimen based on FluCy. All patients un-
derwent an autologous followed by a NMA allogeneic HSCT in
a tandem approach. GVHD prophylaxis combined tacrolimus and
mycophenolate mofetil (MMF). MMF was stopped at day +50 and
tacrolimus tapered between day+80 and day+100. FDC was defined
as . 5 95% donor CD3 circulating cells.
Results: Progression-free (PFS) and overall survival (OS) at 8 years
was respectively 42,7% and 70.7%. All but 8 patients achieved FDC
at day 180. Median time from transplantation to FDC was 120 days.
Four out of the 8 patients with persistent mixed chimerism (MC) ex-
perienced progression, 2 of them before day 100. Graft composition
in CD3 and CD34 cells were correlated (r 5 0.291, P 5 0.009).
CD34 \ 5 x10^6/kg was associated with less cGVHD (73% vs
92% p 5 0,039). CD3\ 25 x10^7/kg was associated with better
Poster Session I S263PFS (53% vs 13%, p5 0,004). Day 100 chimerism does not predict
incidence of cGVHD, relapse, or overall survival. Day 56 chimerism
result was higher for patient who experienced aGVHD (median 89%
vs 78%, p 5 0,048) and was associated with better OS if less than
82.5% (84% vs 53%, p 5 0,01).
Conclusion: Limiting CD34 cell dose could lower incidence of
cGVHD presumably without influencing relapse incidence and
overall survival, while limiting CD3 cell dose could improve survival.
Early evaluation of chimerism at day 56 is relevant to identify pa-
tients who will experience aGVHD and predict survival.160
STEM CELL TRANSPLANT ADVERSE REACTIONS (STAR) ANALYSIS: DOES
A HIGHER INFUSION RED BLOOD CELL CONTENT CORRELATE WITH SE-
RIOUS ADVERSE EVENTS?
Vidula, N., Villa, M., Mehboob, M., Jovanovic, B., Meagher, R.,
Gordon, L.I. Northwestern University Feinberg School of Medicine, Chi-
cago, IL
Introduction: Stem cell transplantation has emerged as a treatment
option for patients with hematologic malignancies. With transplan-
tation, however, there is a risk of adverse events associated with the
stem cell infusion. These events were previously attributed to the
cryoprotectant used in cell preparation, but the persistence of these
events with cryoprotectant depletion suggests the involvement of
other factors. Recently, the red blood cell content of stem cell infu-
sions has been implicated in transplant related adverse events includ-
ing bradycardia and renal toxicity. We analyzed the Northwestern
University transplant experience to determine whether the red blood
cell content of an infusion correlated with serious adverse reactions
such as stroke and seizure.
Methods:We conducted a retrospective chart review of all hemato-
logic malignancy patients at our center who received stem cell trans-
plants between 1/1/08 and 5/1/11. Detailed patient and infusion
characteristics were collected.
Results: We identified 462 hematologic malignancy patients who
received stem cell transplants. The mean red blood cell content
per kilogram body weight of the stem cell infusion for the entire pop-
ulation was 0.25mL/kg6 .34 (range 0.02-4.32mL/kg). Five patients
had serious adverse reactions including stroke (3 patients), seizure (1
patient), and nausea, vomiting, and flushing (1 patient). The mean
red blood cell content per kilogram body weight of the stem cell in-
fusion for these 5 patients with serious adverse events was 0.34 mL/
kg 6 0.20 (range 0.13-0.63).
Conclusions: Our preliminary results suggest that serious adverse
events at the time of stem cell transplantation are generally rare, but
can be devastating. We note a slightly higher red blood cell content
amongst those patients experiencing these types of events compared
to the study population as a whole. However, further study is ongoing
to determine whether there is a correlation between RBC content and
serious adverse events at the time of stem cell re-infusion.161
DESPITE THE USE OF THE COMBINATION OF G-CSF AND PLERIXAFOR
FOR STEM CELL MOBILIZATION, ONE THIRD OF THE PATIENTS WITH
LYMPHOMA WERE STILL ‘‘POOR MOBILIZER’’ USING THE CRITERIA
RECENTLY PROPOSED BY GITMO (\ 2.0 X 106 CD 34 + CELLS PER Kg
in # 3 APHERESIS)
Fung, H.C.1,3, Tornatta, J.1, McLeod, B.1,2,3, Nathan, S.1,3,
Maciejewski, J.1,3, Rich, E.1,3, Karmali, R.1,3, Jimenez, A.1,3,
Christopherson KW II, II,1,3, Gregory, S.A.3 1Coleman Foundation Blood
andMarrow Transpalnt Center, Rush Cancer Center and Rush University
Medical Center, Chicago, IL; 2Rush University Medical Center, Chicago,
IL; 3Rush University Medical Center, Chicago, IL
Background: Gruppo Italian Trapianto di Midollo Osseo
(GITMO) recently proposed a new definition on ‘‘poor mobilizer’’
based on G-CSF (G) +/- chemotherapy based mobilization strategy
(BMT (2011), 1-10). Data on using the combination of G + plerixa-
for (P) for mobilization (Mob) were however not utilized to formu-
late this proposal. Method: In this retrospective analysis, we
examined the Mob kinetic, incidence and characteristics of ‘‘poormobilizer’’ as proposed by GITMO in pts receving G + P for mob.
Between 02/09 & 05/10, 58 consecutive pts with NHL, HD, or
MM underwent Stem Cell Mobilization at our instituion using the
combinaiton of G + P.Mob consisted ofG-CSF 10 mg/kg SC admin-
istered daily at 6:00 am on days 1 through 4 plus plerixafor 0.24 mg/
kg SC given once daily at 5:00 pm in an outpatient clinic beginning
on day 4. Thirty-one (53%) pts had lymphoma (28NHL& 3HD)&
27 (47%) patients had MM. The median age was 57.3 years (range,
30.4-71.1). At the time of mob, all pts except 3 (5%) had chemo-re-
sponsive disease. One third of pts had received. 2 prior chemother-
apy regimens and nearly half (43%) had received prior radiation
therapy. Seven (12%) pts (4 NHL and 3 MM) had undergone previ-
ous mob attempts that did not include P.
Results:Themedian totalCD34+ cell yields were 3.06 106 and 8.27
 106 CD34+ cells/kg for lymphoma and myeloma pts, respectively.
Apheresis yielded an adequate number of CD34+ cells in a median
of 2 days (range, 1-4). The minimum CD34+ cell yield (2  106
CD34+ cells/kg for lymphoma pts; 4  106 CD34+ cells/kg for mye-
loma pts was achieved in 45 (78%) pts, including 23 (74%) lymphoma
and 22 (81%)myeloma patients. 26 of 27 (96%)myeloma pts achieved
yields of$2 x 106 CD34+ cells/kg. 30 (52%) pts (14 [45%] lymphoma;
16 [59%] myeloma) achieved their respective minimum CD34+ cell
yields within 1 apheresis day. On the other hand, 12 (39%) pts with
lymphoma and 1 (4%) pt with myeloma were identified as poor mobi-
lizer using the criteria proposed byGITMO.Advanced disease, refrac-
tory disease, extensive BM involvement or cellularity\ 30% and age
. 65 did not predict for poor mobilization.
Conclusion:Weconclude that despite the use ofG-CSF+P, one third
of the pts with lymphoma are still ‘‘poormobilizer’’ and larger study will
be required to identify predictors for poormobilization for pts usingG-
CSF + P as mobilization strategy. Additional measures are required to
further improve mobilization efficiency for lymphoma pts.162
ANALYSIS OF INF-g AND TNF-a, CXCL-10 CHEMOKINE AND ITS RECEP-
TOR CXCR-3 EXPRESSION IN SKIN BIOPSIES FROM PATIENTS WITH
ACUTE GRAFT-VERSUS-HOST DISEASE
Lemos, G.1,3, Pinto, D.O.1,3, Matos, M.2,3, Bouzas, L.F.2,3,
Abdelhay, E.1,3 1Bone Marrow Transplantation Unit (CEMO) - INCA,
Rio de Janeiro, Brazil; 2Bone Marrow Transplantation Unit (CEMO) -
INCA, Rio de Janeiro, Brazil; 3National Cancer Institute (INCA), Rio
de Janeiro, Brazil
Introduction: Acute graft-versus-host disease (aGVHD) is one of
the most frequent complications in patients undergoing allogenic
hematopoietic stem cell transplantation (HSCTs), occurring in
35% to 50% of cases. The pathophysiology of this disease is charac-
terized by immunological factors causing tissue injury in various or-
gans such as skin, liver and gastrointestinal tract. The skin is usually
the initial target of the disease, and also the organ most affected. Cy-
tokines and chemokines participate in several important inflamma-
tory processes and has been described as important molecules in
the development of aGVHD.
Objective: Evaluate the expression profile of cytokines INF-g and
TNF-a, the chemokine CXCL-10 and its receptor CXCR-3 in
skin biopsies of patients undergoing allogeneic HSCT who devel-
oped or not aGVHD in skin.
Material andMethods:We analyzed by immunohistochemistry, 32
skin biopsies of patients undergoing allogeneic HSCT at the Bone
Marrow Transplantation Center (CEMO-INCA) (24 with and 08
without aGVHD) on day D-8, D0, D +14, D +28 and D +100.
Skin biopsies of healthy donors were used as control.
Results: The labeling of INF-g and TNF-a, CXCL-10 and CXCR-3
in skin biopsies of patientswhohad aGVHDornot remained at the level
of the basal layer of epidermis. However, there was an increased expres-
sion of these molecules in all patients assessed when compared with the
level of expression in skin biopsies of healthy donors. In addition, no sig-
nificant differences were found when comparing the level of expression
of these molecules in pre-HSCT (day D-8) with the day of diagnosis.
Conclusion: These results suggest that the expression of cytokines
INF-g and TNF-a, CXCL-10 chemokine and its receptor CXCR-
3 in skin biopsies of patients does not appear to be related to aGVHD
but with procedures related to transplantation.
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